VG Life Sciences Inc. (USD) VG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is displayed on specific B cells that leads to chronic inflammation. The company also provides metabolic disruption technology (MDT) compounds impede tumor cells that sensitize cancer cells to treatment by disrupting the metabolic strategies those cells use to survive; and Hydroxychloroquine, a MDT compound that can be used in combination with other cancer drugs for treating drug-resistant cancers. In addition, it offers targeted peptide technology (TPT), a technology that eliminates the subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. VG Life Sciences Inc. was formerly known as Viral Genetics Inc. and changed its name to VG Life Sciences Inc. in November 2012. The company was founded in 1995 and is based in Santa Barbara, California. VG Life Sciences Inc. operates as a subsidiary of Feelux Co., Ltd.

VG Life Sciences Inc. (USD) Active

121 Gray Avenue, Santa Barbara, CA, US, 93101

Stock Price USD

Price Change

Last Dividend USD

C-

Latest Rating

VGLS's stock peer is DOMH (Dominari Holdings Inc.)

VGLS's stock peer is HESG (Health Sciences Group, Inc.)

VGLS's stock peer is KLDO (Kaleido Biosciences, Inc.)

VGLS's stock peer is KNBIF (Kane Biotech Inc.)

VGLS's stock peer is MMIRF (MedMira Inc.)

VGLS's stock peer is NBIO (Nascent Biotech, Inc.)

VGLS's stock peer is NTII (Neurobiological Technologies, Inc.)

VGLS's stock peer is OCTHF (Oxford Cannabinoid Technologies Holdings Plc)

VGLS's stock peer is PHGUF (Pharming Group N.V.)

VGLS's stock peer is PKTX (ProtoKinetix, Incorporated)

VGLS's stock peer is PSYBF (PsyBio Therapeutics Corp.)

VGLS's stock peer is RGBPP (Regen BioPharma, Inc.)

VGLS's stock peer is RSPI (RespireRx Pharmaceuticals Inc.)

VGLS's stock peer is SBMFF (Sino Biopharmaceutical Limited)

VGLS's stock peer is SILO (Silo Pharma, Inc.)

VGLS's stock peer is ZIVO (ZIVO Bioscience, Inc.)

Healthcare Biotechnology

VG Life Sciences Inc., a biotechnology company, researches and develops a pipeline of transformative therapies for combat cancer, infectious diseases, and autoimmune diseases caused by chronic inflammation. It offers VG1177, a solution that deploys a synthesized peptide, which uses its superior binding abilities to eliminate the unwanted Class II-associated invariant chain peptide (CLIP) that is displayed on specific B cells that leads to chronic inflammation. The company also provides metabolic disruption technology (MDT) compounds impede tumor cells that sensitize cancer cells to treatment by disrupting the metabolic strategies those cells use to survive; and Hydroxychloroquine, a MDT compound that can be used in combination with other cancer drugs for treating drug-resistant cancers. In addition, it offers targeted peptide technology (TPT), a technology that eliminates the subpopulation of pro-inflammatory immune cells and presents a possible treatment for autoimmune and infectious diseases. VG Life Sciences Inc. was formerly known as Viral Genetics Inc. and changed its name to VG Life Sciences Inc. in November 2012. The company was founded in 1995 and is based in Santa Barbara, California. VG Life Sciences Inc. operates as a subsidiary of Feelux Co., Ltd.

20%

Dcf Rating

20%

Return On Equity

20%

Return On Assets

20%

Debt To Equity

60%

Price To Earnings

20%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
Dividend Data Not Exist

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions